SEOVF
Sernova Biotherapeutics Inc
Price Chart
Latest Quote
$0.11
+0.00 (+0.00%)
Current Price
| Previous Close | $0.11 |
| Open | $0.10 |
| Day High | $0.10 |
| Day Low | $0.10 |
| Volume | 215 |
Stock Information
Note: Financial values converted from CAD to USD
| Shares Outstanding | 361.49M |
| Total Debt | $1.75M |
| Cash Equivalents | $752K |
| Net Income | $-8.50M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $39.76M |
| EPS (TTM) | $-0.03 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $54.78M |
| Income | $-8.50M |
| Book/sh | $-0.04 |
| Cash/sh | $0.00 |
| Employees | 8 |
Financial Ratios
| Quick Ratio | 0.11 |
| Current Ratio | 0.14 |
Returns & Margins
| ROA | -238.26% |
Ownership
| Insider Ownership | 13.18% |
| Institutional Ownership | 0.04% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -2.69 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| SMA200 | $nan |
| RSI | 50.00 |
| ATR | nan |
| Shares Float | 326.68M |
| Rel Volume | 0.01 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| 6 Months | nan% |
| YTD | nan% |
| Year | nan% |
| 3 Years | nan% |
| 5 Years | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-15 | $nan | 215 |
| 2026-06-12 | $0.11 | 400 |
| 2026-06-11 | $0.11 | 0 |
| 2026-06-10 | $0.11 | 600 |
| 2026-06-09 | $0.11 | 10,200 |
| 2026-06-08 | $0.11 | 35,000 |
| 2026-06-05 | $0.12 | 73,500 |
| 2026-06-04 | $0.11 | 65,600 |
| 2026-06-03 | $0.12 | 56,500 |
| 2026-06-02 | $0.12 | 16,800 |
| 2026-06-01 | $0.11 | 300 |
| 2026-05-29 | $0.11 | 1,900 |
| 2026-05-28 | $0.10 | 8,700 |
| 2026-05-27 | $0.11 | 10,500 |
| 2026-05-26 | $0.11 | 43,500 |
| 2026-05-22 | $0.11 | 2,000 |
| 2026-05-21 | $0.12 | 10,200 |
| 2026-05-20 | $0.11 | 6,800 |
| 2026-05-19 | $0.12 | 9,900 |
| 2026-05-18 | $0.13 | 31,000 |
About Sernova Biotherapeutics Inc
Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is based in Mississauga, Canada.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $754,813 | $586,858 | $32,075 | $118,002 |
| Total Expenses | $15,023,024 | $31,663,742 | $40,501,593 | $24,753,761 |
| Other Income Expense | $18,168 | $-322,926 | $35,926 | $-126,058 |
| Net Non Operating Interest Income Expense | $-729,179 | $-198,467 | $1,468,147 | $459,283 |
| Interest Expense Non Operating | $754,813 | $586,858 | $32,075 | $118,002 |
| Operating Expense | $15,023,024 | $31,663,742 | $40,501,593 | $24,753,761 |
| General And Administrative Expense | $7,499,266 | $8,939,000 | $8,427,758 | $7,826,330 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-15,743,466 | $-32,192,135 | $-38,997,520 | $-24,420,536 |
| Net Interest Income | $-729,179 | $-198,467 | $1,468,147 | $459,283 |
| Interest Income | $25,634 | $388,391 | $1,500,222 | $577,285 |
| Normalized Income | $-15,758,909 | $-31,917,648 | $-39,033,446 | $-24,294,478 |
| Net Income From Continuing And Discontinued Operation | $-15,743,466 | $-32,192,135 | $-38,997,520 | $-24,420,536 |
| Net Income Common Stockholders | $-15,743,466 | $-32,192,135 | $-38,997,520 | $-24,420,536 |
| Net Income | $-15,743,466 | $-32,192,135 | $-38,997,520 | $-24,420,536 |
| Net Income Including Noncontrolling Interests | $-15,743,466 | $-32,192,135 | $-38,997,520 | $-24,420,536 |
| Net Income Continuous Operations | $-15,743,466 | $-32,192,135 | $-38,997,520 | $-24,420,536 |
| Pretax Income | $-15,734,035 | $-32,185,135 | $-38,997,520 | $-24,420,536 |
| Special Income Charges | $55,215 | $18,862 | $0 | - |
| Interest Income Non Operating | $25,634 | $388,391 | $1,500,222 | $577,285 |
| Operating Income | $-15,023,024 | $-31,663,742 | $-40,501,593 | $-24,753,761 |
| Depreciation Amortization Depletion Income Statement | $20,690 | $34,092 | $31,302 | $30,807 |
| Depreciation And Amortization In Income Statement | $20,690 | $34,092 | $31,302 | $30,807 |
| Depreciation Income Statement | $20,690 | $34,092 | $31,302 | $30,807 |
| Per Share | ||||
| Diluted EPS | $-0.05 | $-0.10 | $-0.13 | $-0.09 |
| Basic EPS | $-0.05 | $-0.10 | $-0.13 | $-0.09 |
| Other | ||||
| Tax Effect Of Unusual Items | $2,725 | $-48,439 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-14,654,799 | $-30,735,071 | $-38,555,820 | $-23,736,478 |
| Total Unusual Items | $18,168 | $-322,926 | $35,926 | $-126,058 |
| Total Unusual Items Excluding Goodwill | $18,168 | $-322,926 | $35,926 | $-126,058 |
| Reconciled Depreciation | $342,591 | $540,280 | $445,551 | $439,998 |
| EBITDA (Bullshit earnings) | $-14,636,631 | $-31,057,997 | $-38,519,894 | $-23,862,536 |
| EBIT | $-14,979,222 | $-31,598,277 | $-38,965,445 | $-24,302,534 |
| Diluted Average Shares | $328,286,722 | $306,954,330 | $303,332,686 | $273,593,143 |
| Basic Average Shares | $328,286,722 | $306,954,330 | $303,332,686 | $273,593,143 |
| Diluted NI Availto Com Stockholders | $-15,743,466 | $-32,192,135 | $-38,997,520 | $-24,420,536 |
| Tax Provision | $9,431 | $7,000 | $0 | - |
| Gain On Sale Of Ppe | $55,215 | $18,862 | $0 | - |
| Gain On Sale Of Security | $-37,047 | $-341,788 | $35,926 | $-126,058 |
| Research And Development | $7,503,068 | $22,690,650 | $32,042,533 | $16,896,624 |
| Selling General And Administration | $7,499,266 | $8,939,000 | $8,427,758 | $7,826,330 |
| Other Gand A | $2,115,020 | $5,185,783 | $3,209,187 | $1,934,123 |
| Insurance And Claims | $506,444 | $687,831 | $652,792 | $651,393 |
| Salaries And Wages | $4,877,802 | $3,065,386 | $4,565,779 | $5,240,814 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-25,076,830 | $-12,956,608 | $12,197,816 | $47,091,913 |
| Total Assets | $764,234 | $7,527,339 | $22,106,815 | $52,484,921 |
| Total Non Current Assets | $241,584 | $1,057,791 | $1,083,325 | $1,394,313 |
| Non Current Prepaid Assets | $223,860 | $223,860 | $259,164 | $223,860 |
| Current Assets | $522,650 | $6,469,548 | $21,023,490 | $51,090,608 |
| Other Current Assets | $135,013 | $159,170 | $164,664 | - |
| Receivables | $122,633 | $298,104 | $1,052,991 | $1,146,542 |
| Other Receivables | $18,155 | $39,756 | $194,998 | $383,756 |
| Taxes Receivable | $104,478 | $258,348 | $538,607 | $406,035 |
| Cash Cash Equivalents And Short Term Investments | $265,004 | $6,012,274 | $19,805,835 | $49,776,054 |
| Cash And Cash Equivalents | $265,004 | $6,012,274 | $8,721,835 | $3,776,054 |
| Cash Financial | $265,004 | $6,012,274 | $8,721,835 | $3,776,054 |
| Goodwill And Other Intangible Assets | - | $0 | $316,719 | $516,752 |
| Accrued Interest Receivable | - | $0 | $319,386 | $356,751 |
| Prepaid Assets | - | - | $164,664 | $168,012 |
| Other Intangible Assets | - | - | - | $516,752 |
| Other Non Current Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $4,508,662 | - | - | - |
| Total Debt | $4,773,666 | $569,940 | $136,123 | $275,979 |
| Long Term Debt And Capital Lease Obligation | $1,043,533 | $468,484 | $0 | $136,123 |
| Long Term Debt | $1,043,533 | - | - | - |
| Current Debt And Capital Lease Obligation | $3,730,133 | $101,456 | $136,123 | $139,856 |
| Current Debt | $3,730,133 | - | - | - |
| Other Current Borrowings | $3,730,133 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $25,841,064 | $20,483,947 | $9,592,280 | $4,876,256 |
| Total Non Current Liabilities Net Minority Interest | $1,043,533 | $468,484 | $0 | $136,123 |
| Current Liabilities | $24,797,531 | $20,015,463 | $9,592,280 | $4,740,133 |
| Other Current Liabilities | $3,730,133 | - | - | - |
| Current Deferred Liabilities | $12,508,057 | $0 | $95,013 | $0 |
| Payables And Accrued Expenses | $8,559,341 | $19,914,007 | $9,361,144 | $4,600,277 |
| Payables | $6,677,804 | $18,164,097 | $7,512,954 | $3,899,765 |
| Accounts Payable | $5,160,303 | $17,244,417 | $6,850,693 | $3,613,355 |
| Equity | ||||
| Common Stock Equity | $-25,076,830 | $-12,956,608 | $12,514,535 | $47,608,665 |
| Total Equity Gross Minority Interest | $-25,076,830 | $-12,956,608 | $12,514,535 | $47,608,665 |
| Stockholders Equity | $-25,076,830 | $-12,956,608 | $12,514,535 | $47,608,665 |
| Other Equity Interest | $537,142 | $34,421 | - | $3,296,332 |
| Retained Earnings | $-166,102,608 | $-150,359,142 | $-118,167,007 | $-79,169,487 |
| Other | ||||
| Ordinary Shares Number | $332,854,811 | $325,324,786 | $303,332,686 | $303,332,686 |
| Share Issued | $332,854,811 | $325,324,786 | $303,332,686 | $303,332,686 |
| Tangible Book Value | $-25,076,830 | $-12,956,608 | $12,197,816 | $47,091,913 |
| Invested Capital | $-20,303,164 | $-12,956,608 | $12,514,535 | $47,608,665 |
| Working Capital | $-24,274,881 | $-13,545,915 | $11,431,210 | $46,350,475 |
| Capital Lease Obligations | $0 | $569,940 | $136,123 | $275,979 |
| Total Capitalization | $-24,033,297 | $-12,956,608 | $12,514,535 | $47,608,665 |
| Additional Paid In Capital | $21,792,017 | $20,688,462 | $19,693,776 | $12,494,054 |
| Capital Stock | $118,696,619 | $116,679,651 | $110,987,766 | $110,987,766 |
| Common Stock | $118,696,619 | $116,679,651 | $110,987,766 | $110,987,766 |
| Long Term Capital Lease Obligation | $0 | $468,484 | $0 | $136,123 |
| Current Capital Lease Obligation | $0 | $101,456 | $136,123 | $139,856 |
| Current Accrued Expenses | $1,881,537 | $1,749,910 | $1,848,190 | $700,512 |
| Dueto Related Parties Current | $1,517,501 | $919,680 | $662,261 | $286,410 |
| Net PPE | $17,724 | $833,931 | $507,442 | $653,701 |
| Accumulated Depreciation | $-194,811 | $-600,312 | $-506,499 | $-398,043 |
| Gross PPE | $212,535 | $1,434,243 | $1,013,941 | $1,051,744 |
| Machinery Furniture Equipment | $212,535 | $321,990 | $321,990 | $229,811 |
| Other Properties | - | $1,112,253 | $691,951 | $821,933 |
| Other Short Term Investments | - | $0 | $11,084,000 | $46,000,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-10,907,967 | $-18,896,313 | $-30,438,376 | $-14,750,398 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,907,967 | $-18,896,313 | $-30,339,117 | $-14,421,398 |
| Cash Flow From Continuing Operating Activities | $-10,907,967 | $-18,896,313 | $-30,339,117 | $-14,421,398 |
| Investing Activities | ||||
| Investing Cash Flow | $24,958 | $11,119,304 | $34,781,437 | $-46,341,312 |
| Cash Flow From Continuing Investing Activities | $24,958 | $11,119,304 | $34,781,437 | $-46,341,312 |
| Net Other Investing Changes | - | $35,304 | $-35,304 | $-12,312 |
| Capital Expenditure | - | - | $-99,259 | $-329,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $248,639 | $4,959,506 | $0 | $20,279,178 |
| Financing Cash Flow | $5,135,739 | $5,067,448 | $503,461 | $36,664,566 |
| Cash Flow From Continuing Financing Activities | $5,135,739 | $5,067,448 | $503,461 | $36,664,566 |
| Net Other Financing Charges | $64,825 | $261,422 | $675,392 | $323,470 |
| Net Common Stock Issuance | $248,639 | $4,959,506 | $0 | $20,279,178 |
| Common Stock Issuance | $248,639 | $4,959,506 | $0 | $20,279,178 |
| Other | ||||
| Repayment Of Debt | $-112,756 | $-169,230 | $-171,931 | $-168,560 |
| Issuance Of Debt | $4,935,031 | $0 | - | - |
| Income Tax Paid Supplemental Data | $9,403 | $0 | $0 | $0 |
| End Cash Position | $265,004 | $6,012,274 | $8,721,835 | $3,776,054 |
| Beginning Cash Position | $6,012,274 | $8,721,835 | $3,776,054 | $27,874,198 |
| Changes In Cash | $-5,747,270 | $-2,709,561 | $4,945,781 | $-24,098,144 |
| Proceeds From Stock Option Exercised | $0 | $15,750 | $0 | $16,230,478 |
| Net Issuance Payments Of Debt | $4,822,275 | $-169,230 | $-171,931 | $-168,560 |
| Net Short Term Debt Issuance | $3,703,323 | $0 | - | - |
| Short Term Debt Issuance | $3,703,323 | $0 | - | - |
| Net Long Term Debt Issuance | $1,118,952 | $-169,230 | $-171,931 | $-168,560 |
| Long Term Debt Payments | $-112,756 | $-169,230 | $-171,931 | $-168,560 |
| Long Term Debt Issuance | $1,231,708 | $0 | - | - |
| Net Investment Purchase And Sale | $0 | $11,084,000 | $34,916,000 | $-46,000,000 |
| Sale Of Investment | $0 | $11,084,000 | $52,967,750 | $13,000,000 |
| Net PPE Purchase And Sale | $24,958 | $0 | $-99,259 | $-329,000 |
| Sale Of PPE | $24,958 | $0 | - | - |
| Change In Working Capital | $1,736,278 | $11,160,290 | $4,985,797 | $2,946,659 |
| Change In Payables And Accrued Expense | $1,536,650 | $10,592,947 | $4,752,750 | $3,305,507 |
| Change In Prepaid Assets | $24,157 | $5,494 | $3,348 | $-163,812 |
| Change In Receivables | $175,471 | $561,849 | $229,699 | $-195,036 |
| Other Non Cash Items | $523,736 | $-150,484 | $-676,335 | $-838,570 |
| Stock Based Compensation | $2,302,894 | $1,745,736 | $3,903,390 | $7,451,051 |
| Deferred Tax | $-70,000 | $0 | - | - |
| Deferred Income Tax | $-70,000 | $0 | - | - |
| Depreciation Amortization Depletion | $342,591 | $540,280 | $445,551 | $439,998 |
| Depreciation And Amortization | $342,591 | $540,280 | $445,551 | $439,998 |
| Net Income From Continuing Operations | $-15,743,466 | $-32,192,135 | $-38,997,520 | $-24,420,536 |
| Purchase Of Investment | - | $0 | $-18,051,750 | $-59,000,000 |
| Purchase Of PPE | - | $0 | $-99,259 | $-329,000 |
Fetched: 2026-02-02